TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Moderna to Acquire Oriciro Genomics for US $85 million

Friday, February 10, 2023

Moderna has announced it will acquire Japan-based DNA supplier OriCiro Genomics K.K (OriCiro) for $85m, marking the US Company’s first acquisition since its 2010 launch.

Through the acquisition, Moderna will get access to OriCiro's equipment for cell-free plasmid DNA synthesis and amplification, a form of DNA molecule used in the production of mRNA.

According to the firm, the medicines and vaccines in Moderna's portfolio will be supported by OriCiro's synthetic biology and enzyme technology.

The development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases has been made possible by Moderna's mRNA platform, which is built on ongoing advances in basic and applied mRNA science, delivery technology, and manufacturing. For the previous eight years, Moderna has been recognised by Science as a top biopharmaceutical employer.

The mission of OriCiro Genomics, established in December 2018, is to develop and commercialise cell-free plasmid DNA synthesis and amplification methods for use in gene/cell-based therapeutics and synthetic biology.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit